DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Ian Sarembock, MD - is a retired Coronary & Structural Interventionalist and was previously the Harold C. Schott Endowed Chair in Structural Heart at...
Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.
Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in...
